Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine During 18 Months After Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

This article, published in PLoS Medicine, reports on follow-up data from a Phase 3 trial conducted to test the effectiveness of the malaria vaccine candidate RTS,S/AS01 in children and young infants. RTS,S/AS01 prevented many cases of clinical and severe malaria over 18 months after the third dose of vaccine, with the highest impact in areas with the greatest malaria incidence. Vaccine efficacy was higher in children than in infants, but even at modest levels of efficacy, the number of malaria cases averted was substantial. The authors conclude that vaccination with RTS,S/AS01 could be an important addition to current malaria control in Africa.

Author(s): RTS,S Clinical Trials Partnership

Published: 2014

  • Visit web page (English)

    (Located at www.plosmedicine.org)

    Citation: RTS,S Clinical Trials Partnership. Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine During 18 Months After Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites. PLoS Medicine. 2014;11(7):e1001685.